Janux Therapeutics Inc (JANX) disclosed updated findings on its experimental drugs, JANX007 and JANX008, showcasing significant progress in treating metastatic castration-resistant prostate cancer and late-stage solid tumors, respectively.
In the Phase 1a trial for JANX007 among heavily treated patients with advanced prostate cancer, positive outcomes emerged. Notably, escalating doses of JANX007 resulted in notable declines in prostate-specific antigen (PSA) levels, with higher doses demonstrating more substantial responses. Moreover, the observed cytokine release syndrome (CRS) remained manageable, reinforcing the treatment’s favorable safety profile. Janux plans to unveil expansion dose updates later in 2024.
Meanwhile, in the Phase 1a trial for JANX008 targeting solid tumors expressing high levels of EGFR, encouraging clinical activities surfaced. A subject with NSCLC exhibited a remarkable partial response with significant tumor reduction, indicating therapeutic efficacy. Similarly, a patient with RCC demonstrated substantial tumor shrinkage and clinical benefits. The dose escalation phase for JANX008 is ongoing.
The announcement propelled Janux’s stock, reflecting investor confidence in the potential of its T-cell engager platform. Analysts underscore the validation of Janux’s approach, reiterating an optimistic outlook despite the recent stock surge. This affirmation highlights Janux’s undervaluation, attributed to its TRACTr platform’s untapped potential in developing highly effective cancer therapies.
As of the latest update, Janux shares surged by 186.5%, affirming market enthusiasm for the promising advancements in cancer treatment.
